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From August 1998 to October 1999, glycopeptide-resistant enterococci (GRE) were isolated from 23
infected patients at a teaching hospital in Medellín, Colombia. Identification at the species level and by
multiplex polymerase chain reaction assay indicated that all isolates were Enterococcus faecium. The iso-
lates were highly resistant to ampicillin, ciprofloxacin, gentamicin, penicillin, streptomycin, teicoplanin, and
vancomycin; they were susceptible only to chloramphenicol, linezolid, and nitrofurantoin. Determination of
glycopeptide genotype indicated the presence of the vanA gene in all isolates. Molecular typing by pulsed
field gel electrophoresis showed that all isolates were closely related. This study is the first molecular char-
acterization of GRE in Colombia. 
nterococci normally colonize the intestinal tract of
humans and other animals, with urinary tract infection
being the most common enterococcal infection reported in
humans (1). In recent years, enterococci have become impor-
tant nosocomial pathogens: the organisms have been reported
as the second leading cause of urinary tract infections and the
third leading cause of nosocomial bacteremia in hospitalized
patients (2). The most commonly identified species is Entero-
coccus faecalis, followed by E. faecium (3). E. gallinarum, E.
casseliflavus, and E. durans have been reported less often (4,5).
The most important characteristics of these organisms
include their inherent resistance to several antimicrobial
agents and their ability to acquire resistance determinants.
Resistance against such diverse groups of drugs as β -lactams,
macrolides, aminoglycosides, and glycopeptides continues to
evolve. The ability to grow in the presence of glycopeptides
results from the change of the C-terminal residue of pepti-
doglycan precursors (D-Ala) to D-lactate (VanA, VanB, and
VanD phenotypes) (6,7) or D-serine (VanC, VanE, and VanG
phenotypes) (8–10). The change alters the affinity of the gly-
copeptide for its natural target (6). Six different gene clusters
have been described (vanA-B-C-D-E-G) (6,10–12). The most
predominant phenotype in E. faecium is VanA; VanA strains
are highly resistant to both vancomycin and teicoplanin. The
vanA gene cluster is located on transposons or related elements
(6) and has also been found in nonenterococcal species such as
Arcanobacterium ( Corynebacterium)  haemolyticum,  Oers-
kovia turbata, Bacillus circulans, and Streptococcus gallolyti-
cus (13–16). A van cluster with a high degree of homology to
the vanA cluster (designated vanF) has been found in the bio-
pesticide organism Paenibacillus popilliae (17).
Since the initial discovery of glycopeptide-resistant entero-
cocci (GRE) in the United Kingdom (18), nosocomial isolates
of GRE have been reported from around the world (14); these
isolates have also been found in healthy people in the commu-
nity outside the hospital (19). In Latin America, GRE have
been reported in Argentina (20) and Brazil (21). We report
here the first isolation and characterization of a cluster of
VanA-type glycopeptide-resistant E. faecium in a teaching
hospital in Colombia.
Materials and Methods
Bacterial Isolates
Hospital San Vicente de Paul is a 650-bed teaching hospi-
tal providing tertiary care for Medellín, Colombia, and neigh-
boring towns, an area with a population of 1.5 million
inhabitants. From August 1998 to October 1999, we collected
organisms from 23 patients. Enterococci were isolated from
infected patients by classical microbiologic techniques (3).
Identification at the species level was performed by the Vitek
gram-positive card (bioMérieux SA, Marcy l’Etoile, France),
according to the manufacturer’s recommendations. 
Antimicrobial Susceptibility Testing
Initial identification of resistance to vancomycin was per-
formed by the Vitek system (bioMérieux SA). We confirmed
resistance to vancomycin, determining MICs by an agar dilu-
tion method as recommended by the National Committee for
Clinical Laboratory Standards (22) on Mueller-Hinton agar
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plates (ICN Pharmaceuticals Inc., Madison, WI). MICs were
performed in duplicate. The following antimicrobial agents
were obtained as reference powders of known potency and
tested: ampicillin, ciprofloxacin, chloramphenicol, gentami-
cin, penicillin, streptomycin, teicoplanin, vancomycin (ICN
Pharmaceuticals, Inc.), and linezolid (Pharmacia Corp.,
Peapack, NJ). Susceptibility to nitrofurantoin (MIC <32 µg/
mL) was determined by the Vitek system (bioMérieux SA). In
addition to determining MICs, high-level resistance to strepto-
mycin was tested at concentrations of 2 mg/mL; E. faecalis
ATCC 29212 was used as control strain. Three well-character-
ized strains of enterococci belonging to the genotypes vanA
(E. faecium BM4147), vanB (E. faecalis V583), and vanC (E.
gallinarum BM4174) were included as GRE control strains. 
Polymerase Chain Reaction (PCR) for Species 
Identification of Enterococci and the van Genes
For species identification of enterococcal isolates, the
genes encoding D-alanine-D-alanine ligases specific for E.
faecium (ddlE. faecium), E. faecalis (ddlE. faecalis), vanC-1 (E.
gallinarum), and vanC-2 (E. casseliflavus) were detected by a
multiplex PCR assay, as described by Dutka-Malen et al. (23).
Primers D1 (5´ GCTTCTTCCTTTACGACC) and D2 (GTTC-
CAGTCCTAAAAAAC) for the ddl gene of E. avium were
included in the multiplex mixture. A similar multiplex PCR
protocol was performed separately for detection of van genes
by using specific primers for vanA, vanB, vanC-1, and vanC-2
genes (23). E. faecium BM4147 (vanA),  E. faecalis V583
(vanB), and E. gallinarum BM4174 (vanC-1) were used as
control strains. 
Genotyping
Molecular typing was performed by pulsed-field gel elec-
trophoresis (PFGE). Chromosomal DNA was obtained by the
procedure of Antonishyn et al. (24): a loopful of bacterial col-
onies from a 24-h isolate was grown until A600 was 0.1 in brain
heart infusion broth at 37°C. Bacteria were harvested by cen-
trifugation at 4°C, and the pellet was resuspended in cell sus-
pension buffer (1M NaCl, 10 mM Tris-HCl, pH 8.0). The
suspension was embedded in 1.5% agarose and disks were
made. Disks were placed in lysis buffer (6mM Tris-HCl, pH 8,
1 M NaCl, 100 mM EDTA, 0.5% Brij-58, 0.2% Na deoxycho-
late, and 0.5% N-lauroyl sarcosine) with additional RNase (20
µg/mL) and lysozyme (1 mg/mL) and incubated for 4 h at
37°C. The disks were washed with EDTA-sarcosine buffer
(0.5 M EDTA, pH 8, and 0.1% N-lauroyl sarcosine), placed in
proteinase K solution (100 µg/mL), and incubated overnight at
50°C with mild agitation. Disks were washed four times with
Tris-EDTA buffer (Tris 10 mM, pH 7.5, and 1mM EDTA) for
30–60 min at room temperature on a rocker. 
DNA was digested as described (25). Briefly, DNA fixed
in the agarose disks was preincubated in 1 mL of buffer E (6
mM Tris, pH 8, 20 mM KCl, 6 mM MgCl2, and 6 mM 2-mer-
captoethanol) at 25°C for 30 min. Restriction was performed
for 17 h in 60 µL of restriction buffer containing SmaI (20 U)
at 25ºC. The reaction was stopped by addition of 10 µL of ster-
ile loading buffer. Gels were prepared with 1% agarose in 0.5x
TBE buffer (50 mM Tris, pH 8, 50 mM boric acid, 0.2 mM
EDTA). A DNA ladder (50–1000 kb) was used as the molecu-
lar size marker. Fragments were separated by electrophoresis
(CHEF-DR II system, Bio-Rad Laboratories, Inc., Richmond,
CA) at 6 V/cm, with switch times ramped from 1 s to 35 s over
23 h at 14°C. After staining with ethidium bromide, the
restricted DNA fragments were viewed under UV light and
photographed. A vancomycin-susceptible strain of E. faecium
isolated in the same hospital was included in the PFGE proto-
col as the control. We interpreted the band patterns by the cri-
teria of Tenover et al. (26). 
Results
GRE Isolates and Identification
From August 1998 to October 1999, 23 GRE were col-
lected from the same number of patients hospitalized in vari-
ous wards in Hospital San Vicente de Paul. The first isolate
was recovered from the pleural fluid of a patient hospitalized
in the surgical ward. Isolates came from urine (35%), perito-
neal fluid (22%), surgical wound (17%), intra-abdominal
abscess (13%), pleural fluid (9%), and bile (4%). Molecular
identification by PCR showed that all isolates were E. faecium,
in agreement with the results of the Vitek gram-positive identi-
fication card (bioMérieux SA). 
Antimicrobial Susceptibility Testing
All isolates had high levels of resistance to ampicillin
(MICs 128–256 µg/mL), ciprofloxacin (>32 µg/mL), gentami-
cin (1,024 µg/mL), penicillin (256–512 µg/mL), streptomycin
(>2,000 µg/mL), teicoplanin (>32 µg/mL), and vancomycin
(512 µg/mL). The isolates were susceptible to chlorampheni-
col (4–8 µg/mL), linezolid (1 µg/mL), and nitrofurantoin (<32
µg/mL).
PFGE and Glycopeptide-Resistant Genotype
Analysis of PFGE patterns obtained with the 23 E. faecium
isolates showed that 21 isolates had the same banding pattern.
The remaining two isolates had an additional band around 242
kb (Figure, lanes 2 and 15), indicating that all isolates were
closely related (26). This finding suggests the presence of a
bacterial clone spreading through different wards during the
period of the study. The vanA gene was detected in all isolates,
in agreement with the antimicrobial susceptibility tests (high-
level resistance to both vancomycin and teicoplanin).
Discussion
The emergence of multiresistant GRE is a serious nosoco-
mial problem with important implications for hospital infec-
tion control. Although the geographic distribution of GRE is
worldwide, the epidemiology appears to differ within and
across regions. For example, isolates from hospitalized
patients in France were shown to be genetically unrelatedEmerging Infectious Diseases  •  Vol. 8, No. 9, September 2002 963
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(27,28); a similar situation has been documented in the United
Kingdom (29). In a study of >1,000 isolates of GRE in the
United Kingdom, most were E. faecium and the VanA pheno-
type, accounting for 88% of all isolates (30). Although PFGE
showed a marked genetic diversity within strains, a common
clone was demonstrated in 16 hospitals. In Europe, sources
outside hospitals were confirmed as the source of GRE:
clonally related vancomycin-resistant enterococci strains have
been identified in patients, farm animals, animal products, and
the environment, including the presence of GRE in raw meat
for human consumption (31–34). Avoparcin, a glycopeptide
administered as a growth promoter to farm animals in Europe
from 1975 to 2000 (when it was withdrawn from the market),
has been implicated as an important factor for the emergence
of GRE (31,35). In the United States, dissemination of clonally
related strains of GRE was commonly seen in the early stages
of the epidemic (14). However, a diverse set of strains has
emerged (36). The increased prevalence of GRE in the United
States appears to be related to the massive use of vancomycin
in hospitals, which by far exceeds the use in Europe (37). 
GRE have been found in other parts of Latin America
(Argentina and Brazil) (20,21). Results from the SENTRY
Antimicrobial Surveillance Program 1997–1999 (38) indicated
a low incidence of GRE in Latin America; of 367 isolates,
only three had resistance to glycopeptides (two belonged to the
VanA phenotype and one VanC-type) (38). This report
describes the first characterization of GRE in Colombia; our
findings indicate that GRE are emerging as important nosoco-
mial pathogens there. In fact, GRE have now become preva-
lent in Hospital San Vicente de Paul, and dissemination of
isolates to other hospitals in the country is likely. A multicen-
tric surveillance study carried out in 14 teaching hospitals
(including five major Colombian cities) from March 2001 to
March 2002 indicated that GRE have also been detected in
other hospitals, mainly in the capital city of Bogotá, with a
prevalence of 10% among clinical isolates of enterococci. Phe-
notypic characterization demonstrated the presence of both
VanA and VanB isolates (39). Of VanA-E. faecium, only four
had resistance patterns identical to the Medellín isolates
described in this study. Genotypic characterization of these
isolates is currently under way. 
PFGE analysis of the isolates strongly suggests the dissem-
ination of a single clone among hospitalized patients: the
emergence of GRE in Colombia is likely to follow a trend sim-
ilar to the one in the United States. These data may be signal-
ing the start of an epidemic. Factors directly related to the
emergence of GRE in Colombia have not been studied prop-
erly; glycopeptides appear to be widely used in teaching hospi-
tals, and this situation might be related to the increasing
prevalence of methicillin-resistant Staphylococcus aureus in
the last 4 years (40). Little is known about the use of antimi-
crobial compounds in animals for human consumption.
Strategies to control the spread of GRE in Hospital San
Vicente included monitoring the stringent use of vancomycin
and third-generation cephalosporins, providing education to
personnel throughout the hospital (especially critical-care
units), and implementing infection control measures according
to the Hospital Infection Control Practices Advisory Commit-
tee (41), strongly emphasizing early detection by the microbi-
ology laboratory of patients colonized or infected with GRE.
With these measures, we have decreased the incidence of
cases. However, we have not achieved total eradication; in
2001, the prevalence of GRE was 15%. 
Resistance of enterococci to multiple antibiotics is com-
mon, making treatment problematic. Studies suggest that
enterococci inhibited in vitro by <64 µg/mL of ampicillin may
be susceptible in vivo to high-dose ampicillin or therapy with
ampicillin-sulbactam and gentamicin (if the isolate does not
exhibit high-level resistance to gentamicin) (36). However, the
isolates from this study exhibited high-level resistance to
ampicillin (MIC 128 µg/mL), gentamicin (>1,000 µg/mL), and
streptomycin (>2,000 µg/mL), which further limits the thera-
peutic alternatives. Ciprofloxacin is an antibiotic that has been
used as an alternative for the treatment of GRE infections (42),
but it was inactive against the isolates examined here. 
As found by others (42–44), chloramphenicol was one of
the two agents that retained in vitro activity against GRE in
this investigation. In a retrospective study of 14 patients with
clinical responses, 57% showed improvement after treatment
with chloramphenicol (43). Microbiologic response was 73%
in 11 patients evaluated in the same study (43). Although no
lasting adverse effect related to use of the drug occurred, treat-
ment with chloramphenicol was discontinued for two patients
because of chloramphenicol-induced bone marrow suppres-
sion (43). In another study of 51 patients with bloodstream
infection due to vancomycin-resistant E. faecium, 61% and
79% showed a clinical and microbiologic response to chloram-
phenicol, respectively, but no corresponding decrease in
deaths occurred (45). In our study, patients with urinary tract
infections (UTI) (eight cases) were initially treated success-
fully with nitrofurantoin (100 mg/6 h). Ampicillin (12 g/day)
was used in patients with infections other than UTI. In the lat-
Figure. Pulsed-field gel electrophoresis restriction fragment patterns of
SmaI-digested genomic DNA obtained from glycopeptide-resistant
Enterococcus faecium isolated at San Vicente de Paul Hospital, Medel-
lin, Colombia. Lane 1: a susceptible isolate of E. faecium; lane 2–24:
Restriction patterns of the 23 VanA-type E. faecium. MWM, molecular
weight marker.RESEARCH
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ter group, however, the death rate was 33%, mostly because of
severe sepsis. Chloramphenicol was not used in this group of
patients. Although no controlled trials have demonstrated the
effectiveness of chloramphenicol for the treatment of GRE,
this antibiotic could be a therapeutic alternative in Colombia. 
Linezolid, a new compound from the oxazolidinone group,
has just been launched in Colombia; our findings indicate that
it was active against all isolates tested. Linezolid has emerged
as a therapeutic alternative for multiresistant GRE in Colom-
bia, as in other parts of the world where it is currently avail-
able. However, linezolid-resistant E. faecium clinical isolates
have already been reported in relation to long courses of ther-
apy (21–40 days) (46). A linezolid-resistant E. faecium iso-
lated from a patient without prior exposure to an
oxazolidinone has also been described (47).
In this study, we report the first isolation and characteriza-
tion of a multiresistant cluster of VanA-type E. faecium in a
Colombian hospital. The emergence of this problem and the
limitation of therapeutic options require the implementation of
specific infection control measures and antibiotic policies to
avoid further dissemination.
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